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ABSTRACT 
Objective: The present study aims at implementing the doctor of pharmacy services in the identification and reporting of drug-related problems in 
the in-patient units of cardiology and pulmonary medicine departments of ESI Hospital, Bangalore.  
Methods: A prospective interventional study was conducted from September 2018 to March 2019. Determination and categorization of drug-
related problems (DRPs) were performed by the pharmacist using the PCNE classification scheme for drug-related problems V5.01. The DRPs 
identified by the pharmacist were reported and interventions made were subsequently recorded. 
Results: 180 drug-related problems were identified in the study, among which the major problems were drug-drug interactions (13.88%), followed 
by generic substitution (10%). The mean drug-related problem per patient was found to be 1.06. A total of 196 interventions were made by the 
clinical pharmacists among which, 109 (55.61%), 56 (28.57%), 17 (8.67%) interventions were at the prescriber, drug, patient levels, and 14 
(7.14%) cases were the rest of interventions or activities. Distributions based on type and degree of acceptance of interventions showed that among 
56 drug regimen change interventions proposed by the pharmacist, only 55.35% were accepted. The results further indicated that out of 68 
monitoring required interventions made by the pharmacist, and among 17 cases that required counseling by the pharmacist in verbal, 77.94% and 
88.36% of cases were accepted, respectively. Also, regarding the cases that required communication between the pharmacists and other healthcare 
professionals, 85.36% of a total of 41 samples and all of 14 adverse drug reporting cases made in a formal note form were accepted. 
Conclusion: The clinical pharmacist’s/doctor of pharmacy professional’s timely interventions in the patient’s drug therapy is required to prevent or 
minimize the occurrence and the risk of DRP. Rational drug therapy and optimal medication safety can be achieved by clinical pharmacy services.  
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INTRODUCTION 
Drug therapy can improve the quality of life while treating and 
counteracting or mitigating side effects in various conditions. Drugs 
are, however, powerful and should be appropriately dealt with. A 
drug-related problem (DRP) has been defined as an event or 
circumstance involving drug therapy that actually or potentially 
interferes with desired health outcomes [1]. Alternatively, a DRP is 
an undesirable patient experience that involves drug therapy and 
that actually or potentially interferes with a desired patient outcome 
[2]. To meet a DRP for an event, at least two conditions must be met: 
(1) a patient experiences, or must be likely to experience, disease or 
symptomatology; and (2) these conditions must have an identifiable 
or suspected relationship with drug therapy [3]. 
Drug-related problems are common among the wards of a hospital [4]. 
The patient, not the drug product, is the main focus of the pharmacist's 
decisions and actions. Creating practice standards for pharmacists 
reflecting the pharmacist's ability to detect, solve, and prevent patient-
specific DRPs is straightforward. Pharmacist's functions would be 
arranged accordingly so that providing the essence around which to 
structure standards of practice. The patient itself and the patient's 
desired pharmacotherapeutic outcomes and the pharmacist's ability to 
reach these outcomes are associated with their focuses mentioned 
earlier [5]. Generally, DRP incorporates Adverse Drug Reactions 
(ADRs), Drug Errors (DE), and Drug Interactions (DI). 
The World Health Organization (WHO) defines an adverse drug 
reaction (ADR) as “a reaction which is noxious and unintended, and 
which occurs in doses normally used in human for prophylaxis, 
diagnosis, or therapy of disease, or modifying the physiological 
functions” [6]. The American Society of Health-Systems Pharmacists 
(ASHP) provides guidelines and emphasizes the role of pharmacists 
in comprehensive ADR management [7]. The corresponding tips 
include risk minimization technique, for example, grasping the 
patient’s opinion about drug therapy, training with the patient to 
comprehend the treatment benefits, and recognition and detection 
techniques such as understanding known ADRs, examining the pre-
existing symptoms of the patient, investigating new clinical 
presentations as conceivable ADRs, observing wellbeing conditions, 
labs, or other factors revealing the symptoms, applying probability 
tools, e. g., the Naranjo adverse drug reaction probability scale or 
4Ts for heparin-induced thrombocytopenia, to name a few [8]. The 
pharmacist and prescriber have to make sure patients are informed 
about the side effects and the appropriate treatments applied. 
Pharmacists, thanks to detailed knowledge of medicine, can relate 
unexpected symptoms experienced by patients to possible adverse 
effects of their drug therapy. The practice in clinical pharmacy needs 
to make sure that ADRs are minimized by avoiding drugs with 
potential side effects in susceptible patients. Thus, a pharmacist has 
an important role in the prevention, detection, and reporting of 
ADRs [9]. There are various scales to assess ADRs and establish a 
causal relationship between the adverse event and medication. 
These scales include the Naranjo ADR probability scale, WHO-
Uppsala monitoring center causality categories, the severity of 
reported ADRs by Modified Hartwig, and the Siegel scale. 
A drug interaction is a situation in which a substance (usually 
another drug) affects the activity of the other drug when both are 
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administered together [10]. Drug interactions can be classified into 
three broad categories, including drug-drug interaction, drug-food 
interaction, and drug-condition interactions, and they could be a 
major source of drug-related problems. The practice in 
clinical pharmacy ensures that drug interactions are minimized by 
avoiding drugs with potential side effects in susceptible patients. 
A medication error is a preventable event that may cause 
inappropriate medication prescription or harm to the patient while 
the medication is in the control of the healthcare professional, 
patient, or consumer [11]. The pharmacist can contribute to 
reducing such errors through applying various strategies such as 
educating health care providers and patients, implementing 
medication reviews and reconciliation, using computerized systems, 
and prioritizing areas for quick wins [12]. 
Studies have revealed that pharmaceutical care interventions have 
the potential for reducing hospitalization and drug therapy 
problems [13]. The goal of the pharmacist is to provide 
pharmaceutical care, which is the direct, responsible provision of 
medication-related care to achieve definite outcomes that improve 
a patient's quality of life. Cardiovascular and pulmonary diseases are 
often accompanied by comorbidities and complications, so multiple 
drugs are prescribed in this condition; thus, these diseases more 
liable to be exposed to DRPs. Therefore, pharmacist interventions in 
this area are of great importance. So, given that the patients are 
exposed to DRPs, which affect their quality of life, the present study 
is conducted to determine the impact of pharmacy services in the 
identification and reporting of DRPs in the in-patient units of 
cardiology and pulmonary departments of a primary care hospital. 
MATERIALS AND METHODS  
A prospective, observational, and interventional study was 
conducted for the identification of DRPs, underlying causes, viable 
interventions, and their outcomes in a primary care hospital. The 
duration of the study was a period of six months between September 
2018 and March 2019. Only patients admitted to two departments 
(pulmonary and cardiology) were included. A sample size of 169 
patients with pulmonary/cardiac diseases was randomly selected. 
The study protocol was approved by the Institutional Ethics 
Committee before the commencement of the study (Protocol No: 
GCP/IEC-09/2018-2019). The details of patients’ medication 
therapy were collected from medication charts provided in the 
nursing station. The pharmacist determined and categorized DRPs 
using the PCNE classification scheme for Drug-Related Problems 
V5.01. The DRPs identified by the pharmacist were reported and 
interventions made were subsequently documented. 
The following tools were used to collect the data:  
1. Patient data collection form 
2. Suspected ADR identification and reporting form 
3. ADR notification form (adverse drug reaction form) 
4. DI Form (drug interaction form) 
5. Medication error reports form 
Recording and calculation of enlisted subject’s data were done using 
Microsoft Excel and Prism GraphPad Software. 
RESULTS 
Cardiology department 
65 out of 169 cases were cardiac patients. The maximum percentage 
of patients (43.07%) was in the age group of 50–60 y, and the 
dominant gender (67.69%) was male. The mean age was found to be 
49.30±11.63. Distribution of comorbidities among the study 
population in the cardiology department showed that the most 
prevalent type of comorbidity was hypertension (35.38%), followed 
by hyperlipidemia (32.3%). The mean presence of comorbidity was 
found to be 1.55 per patient (table 1). 
Pulmonary department 
104 out of 169 cases were pulmonary patients. The maximum 
percentage of patients (31.73%) was in the age group of 50–60 y, and 
similar to the Cardiology department, the majority (59.61%) were male. 
The mean age was found to be 45.9±12.34. Distribution of comorbidities 
among the study population in the pulmonary department showed that 
the most prevalent type of comorbidity was hypertension (19.77%), 
followed by a viral infection (19.20%). The mean presence of 
comorbidity was found to be 1.70 per patient (table 1). 
 
Table 1: Baseline characteristics 
Parameter Frequency (%) 





















































A total of 169 prescriptions were collected from both cardiology and 
pulmonary departments among which 133 (79%) prescriptions 
were involved in DRPs (table 2). 
Among drugs involved in drug-related problems, the most 
frequently involved drug was theophylline (21.95%), followed by 
antacids (19.51%) (table 3). 
According to table 4, 180 drug-related problems were identified in 
the study. The major problems were drug-drug interactions 
(13.88%), followed by generic substitution (10%). The mean drug-
related problem per patient was found to be 1.06. 
A total of 196 interventions were made by the clinical pharmacists 
among which, 109 (55.61%) interventions were at the prescriber 
level, 56 (28.57%) interventions were at the drug level, 17 (8.67%) 
were at the patient level, and 14 (7.14%) were other interventions 
or activities (table 5). 
Distribution based on the type and degree of acceptance of 
interventions showed that among 56 drug regimen change 
interventions proposed by the pharmacist, only 55.35% were 
accepted, while most of them 41 (73.21%) were in the formal 
note form. Out of 68 monitoring required interventions made by 
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the pharmacist, about 77.94% were accepted, whereas the 
majority of them were in the formal note form (83.82%). Among 
17 cases that required counseling by the pharmacist in verbal, 
about 88.36% were accepted. Out of 41 cases that required 
communication between the pharmacists and other healthcare 
professionals, 85.36% of cases were accepted, and all 14 adverse 
drug reporting cases made in a formal note form, were accepted 
(table 6). 
 
Table 2: Distribution of the number of prescriptions involved in 
DRP (n=169) 
Prescriptions involved in DRP Number of prescriptions (%) 
Prescriptions with DRP 133 (79%) 
Prescriptions without DRP 36 (21%) 
 
Table 3: Distribution of most common drugs involved in drug-
related problems (n=41) 
Drugs Frequency (%) 
Antacids 8 (19.51) 
Aspirin 4 (9.75) 
Corticoids 7 (17.07) 
Digoxin 4 (9.75) 
Rifampin 3 (7.31) 
Theophylline 9 (21.95) 
Warfarin 6 (14.63) 
Table 4: Distribution of drug-related problems that are 
identified and reported by the doctor of pharmacy in in-patient 
units of cardiology and pulmonary departments (n=180) 
Types of drug-related 
problems 
The total frequency of drug-
related problems that are 
identified and reported by 
clinical pharmacist (%) 
Adverse drug reaction 14 (7.77) 
Drug-allergy interactions 14 (7.77) 
Drug-disease contraindications 16 (8.88) 
Drug-drug interactions 25 (13.88) 
Generic substitution 18 (10.00) 
Inappropriate duration of drug 
treatment 
17 (9.44) 
Incorrect drug dosage 12 (6.66) 
Laboratory test omitted 12 (6.66) 
Over and underutilization 17 (9.44) 
Therapeutic duplication 10 (5.55) 
Therapeutic inappropriateness 10 (5.55) 
Untreated indication 15 (8.33) 
 
Table 5: Distribution of level of interventions made by the 
pharmacist (n=196) 
Intervention level Frequency of activities (%) 
At prescriber level 109 (55.61) 
At patient level 17 (8.67) 
At drug level 56 (28.57) 
Other interventions or activity 14 (7.14) 
 
Table 6: Distribution of types of pharmacist’s clinical interventions and degree of acceptance 
Intervention type Method Number of reports (%) Acceptance 
Yes (%) No (%) 
Drug regimen change (n=56) Verbal 15 (26.78) 31 (55.35) 25 (44.64) 
Write a formal note 41 (73.21) 
Monitoring required (n=68) Verbal  11 (16.17) 53 (77.94) 15 (22.38) 
Write a formal note 57 (83.82) 
Counseling required (n=17) Verbal  17 (100) 15 (88.23) 2 (11.76) 
Communication (n=41) Verbal 41 (100) 35 (85.36) 6 (14.63) 
Adverse drug reporting (n=14) Write formal note 14 (100) 6 (100) 0 (0) 
 
DISCUSSION 
In the present study, 65 patients were admitted to the cardiology 
department, out of which the majority of patients (43.07%) were in 
the age group of 50–60 and, the mean age was found to be 
49.30±11.63. The results are comparable to the observations from 
the study conducted by Javedh Shareef (2014) [14], which 
demonstrated that most of the study population was in the age 
group of 41–60 y. These findings may suggest that older patients are 
more exposed to the risk of developing cardiac diseases due to age 
progression and comorbidities. 
Gender-wise classification of the study population in the cardiology 
department implied that out of 65 patients, 67.69% of cases were 
male, and the rest (32.30%) were female. In contrast, Ousman 
Abubeker Abdela et al. (2016) [15], showed that the majority of the 
study population were female (63%). This difference suggests that 
the risk of developing heart disease is not affected by gender and is 
more influenced by other risk factors. 
Distribution of comorbidities among the study population in the 
cardiology department showed that the most prevalent type of 
comorbidity was hypertension (35.38%), and the mean presence of 
comorbidity was found to be 1.55 per patient. In a similar study 
conducted by Ousman Abubeker Abdela et al. (2016) [15], about 
(43.1%) patients were over five comorbidities (mean value 5.8±0.8). 
On the other hand, the mean value for the number of drugs per 
patient was found to be 5.1, while it was 3.5±1.5 in the study 
conducted by Ousman Abubeker Abdela et al. (2016) [15]. Hence, it 
can be inferred that the presence of comorbidities, the number of 
drugs prescribed per patient, and the development of drug-related 
problems among patients with cardiac diseases are correlated. 
In the pulmonary department, 59.61% of patients were male while 
the remaining (40.38%) were female. Shreds of evidence from 
different studies indicate that gender influences the incidence, 
susceptibility, and severity of several lung diseases. Data from both 
human and animal studies suggest that sex hormones may 
contribute to disease pathogenesis or serve as protective factors, 
depending on the disease involved. Also, it is observed that men are 
more vulnerable to most lung diseases stemming from higher 
smoking rates in men [16]. 
Consideration of patients based on the reason for admission showed 
that most of the patients (31.73%) suffered from Chronic 
Obstructive Pulmonary Disease (COPD). Moreover, the mean age 
was found to be 45.9±12.34. Similar results were reported by 
Madhuragauri Shevade et al. (2015) [17]; indicating that the most 
common respiratory disease was COPD (29.6%), among patients 
with a mean age of 43.6±18.5 y. Accordingly, the prevalence of COPD 
disease among this age group is more than other ages, which can be 
due to the habits of smoking and tobacco chewing. The observations 
found from the present study indicate that the habit of smoking was 
more prevalent among 40-to 50-year-old patients (12.50%), so 
higher risk of COPD is expected among older patients. 
A total of 169 prescriptions were collected from both cardiology and 
pulmonary departments among which, 133 (79%) prescriptions 
were involved in DRPs, and the mean drug-related problem per 
patient was found to be 1.06. Likewise, a mean number of 1.17±1.1 
DRP per patient [15] and 2.6±1.8 DRPs per patient [18] were 
reported elsewhere. In both studies, the underlying risk factor was 
found to be polypharmacy. Similarly, the present study found 
polypharmacy, with a mean number of more than 5 drugs in each 
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department, which was the result of the presence of comorbid 
conditions. 
Based on the distribution of drug-related problems that are 
identified and reported by the doctor of pharmacy in in-patient units 
of cardiology and pulmonary departments, the most prevalent DRPs 
found in respective departments are drug-drug interaction 
(13.88%), followed by generic substitution (10%), which is 
comparable to the results reported by Cecilia Peterson et al. (2017) 
[19], which shows that the most common DRPs were interactions. 
This is justified because multiple drug regimens (polypharmacy) 
were applied to patients because of suffering from multiple diseases. 
Distribution based on type and degree of acceptance of 
interventions in the present study showed that most of the 
interventions made by the pharmacist at different levels were 
accepted. This is comparable to the findings in Qatar, which 
indicated that most of the interventions (53%) were accepted [20]. 
The results suggest that the pharmacy practice and its role in 
improving patient quality of life and applying appropriate 
medication have almost been accepted among health care 
professionals and patients. 
CONCLUSION  
The present study concludes that the clinical pharmacist’s/doctor of 
pharmacy professional’s timely interventions in the patient's drug 
therapy is required to prevent or minimize the occurrence and risk 
of DRP. Rational drug therapy and optimal medication safety can be 
achieved by clinical pharmacy services. 
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